Related Experiment Video
Updated: Apr 16, 2026
06:39
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
1.6K
Abstract:
Increases in the INR and cases of bleeding have been reported during concomitant use of miconazole oral gel or mucoadhesive buccal tablets and a vitamin K antagonist (fluindione or warfarin).
Insights
Concomitant use of miconazole oral products with vitamin K antagonists like warfarin may increase INR levels and bleeding risk. Patients should be aware of potential drug interactions and monitor for adverse effects.
Area of Science:
- Pharmacology
- Clinical Medicine
- Drug Interactions
Background:
- Vitamin K antagonists (VKAs) are crucial anticoagulants.
- Miconazole is an antifungal medication with known drug interaction potential.
- Concomitant use of certain drugs can alter VKA efficacy and safety.
Purpose of the Study:
- To investigate the interaction between miconazole oral formulations and VKAs.
- To assess the impact of miconazole on INR levels and bleeding events in patients taking VKAs.
Main Methods:
- Observational reports of patients using miconazole oral gel or mucoadhesive buccal tablets concurrently with fluindione or warfarin.
- Monitoring of International Normalized Ratio (INR) values.
- Documentation of bleeding events.
Main Results:
- Reported increases in INR.
- Observed cases of bleeding in patients during concomitant use.
- Potential for significant drug interaction between miconazole oral products and VKAs.
Conclusions:
- Concomitant administration of miconazole oral products and VKAs requires caution.
- Close monitoring of INR and potential bleeding is recommended.
- Further studies may be warranted to elucidate the precise mechanisms and quantify the risk.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
01:30Drug toxicity: Drug–Drug Interaction
379
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
379
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:25Pharmacokinetics: Drug–Drug Interactions
753
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
753
01:15Antifungal Agents
100
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
100
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K